


# Q2 2024 Conference Call

Anita Johansen, CEO Per Lindblad, CFO

Lund, 16 July, 2024



### Safe Harbor Statement

This presentation contains certain forward-looking information that reflects Probi's present view of future events, as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information. Given the risks associated with forward-looking statements, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements referred to above speak only as at the date of the presentation. Probi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect future events, circumstances, anticipated events, new information or otherwise except as required by law or by any appropriate regulatory authority.

Probi does not make any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this presentation, and no reliance should be placed on such information. Probi does not accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.







- 1. Q2 highlights
- 2. Financial Review
- 3. Outlook
- 4. Q&A



### **Q2** highlights – A quarter marked by significant progress

#### **Financials**

- Q2 was a strong quarter showing significant growth
- Net sales totaled SEK ~179 m, a +25% increase
- Net sales in the first half of the year are in line with expectations
- EBITDA margin of Q2 was 19%
- The Annual General Meeting decided on a SEK 1.30 per share dividend

#### **Operations**

- We continued to streamline and adapt the organization to facilitate growth and profitability
- Our Matas partnership went live making Probi® consumer products available in Denmark
- The Probi® Sensia product received further validation by a 4th study focused on gut-brain health in older adults
- We entered a partnership with Bower to incentivize recycling in B2C in the Nordic markets
- We launched first ever China Innovation Day, igniting considerable interest among customers
- Our customer project pipeline is growing as a result of a generally high commercial activity










- 1. Q2 highlights
- 2. Financial Review
- 3. Outlook
- 4. Q&A



#### A strong overall business performance

#### Net sales

SEK m, reported sales growth in % (constant currency growth)



### EBITDA % EBITDA margin as % of Net sales



#### **Key aspects**

- Strong Q2 sales performance due to a combination of favorable comparatives and new business wins
- The growth is driven by AMERICA and EMEA
- A major uptick in the EBITDA margin due to a favorable product and customer mix
- Performance aligns with our expectations and compensates for the weaker Q1 results, effectively balancing our overall performance for H1




#### YTD Net Sales and Gross Profit by region

Net sales SEK m sales growth in % (constant currency growth)

**Gross profit** SEK m


Gross margin





### **Volume drives higher Net income**

### **Reconciliation of net income** SEK m



#### **Key aspects**


- Net income increased by SEK 14 m.
  - Volumes effect
    - Driven by low comparisons in Q2 2023
    - Business wins
  - Opex
    - Timing of especially Marketing & Sales and R&D expenses





#### Probi maintain strong cash position

### **Reconciliation of group liquidity** SEK m



#### **Key aspects**


- Operating cash flow of SEK 23 m
- CapEx of SEK -27m mainly due to investments in manufacturing facilities, including projects to help drive efficiencies as well as R&D projects
- Financing includes payments of lease obligations interest on bank funds
- Dividend payout as decided by AGM in May



probi first in probiotics

#### Solid balance sheet with no external loans

### Balance sheet as per June 30, 2024 SEK m




#### **Key aspects**

- Total equity of SEK 1 415 m.
- Equity ratio 89%
- No external loans







- 1. Q2 highlights
- 2. Financial Review
- 3. Outlook
- 4. Q&A



## Progressing in the right direction

- Q2 marks a positive milestone, verifying Probi's reinforced strategy
- Our organizational capabilities and ways of working has improved
- Commercial activity is high all through the organization, which has resulted in a positively trending customer project pipeline
- Production optimizations are progressing according to plan and initial data shows positive results
- We will maintain our strategic focus while implementing important changes and improvements during the ongoing transition





- 1. Q2 highlights
- 2. Financial Review
- 3. Outlook
- 4. Q&A





### Financial calendar

Interim report Q3 2024 (Year-end report 2024

October 22, 2024 January 28, 2025

